Table 2 Treatment and patient outcomes
|  | All patients (n = 68) | Low sPD-L1 (n = 36) | High sPD-L1 (n = 32) |  | |||
|---|---|---|---|---|---|---|---|
| Â | n | (%) | n | (%) | n | (%) | P |
HD-MTX chemotherapy | |||||||
 Completed | 61 | (90) | 32 | (89) | 29 | (91) | >  0.999 |
 Failed to complete | 7 | (10) | 4 | (11) | 3 | (9) |  |
Response to HD-MTX treatment | |||||||
 CR/PR | 54/12 | (97) | 30/6 | (100) | 24/6 | (94) | 0.486 |
 SD/PD | 1/1 | (3) | 0/0 | (0) | 1/1 | (6) |  |
Intrathecal chemotherapy | |||||||
 Combined | 26 | (38) | 10 | (28) | 16 | (50) | 0.081 |
 Not combined | 42 | (62) | 26 | (72) | 16 | (50) |  |
Whole brain radiotherapy | |||||||
 Done | 45 | (66) | 24 | (67) | 21 | (67) | >  0.999 |
 Not done | 23 | (34) | 12 | (33) | 11 | (34) |  |
Relapse after primary treatment | |||||||
 No relapse | 29 | (43) | 18 | (50) | 11 | (34) | 0.226 |
 Relapse | 39 | (57) | 18 | (50) | 21 | (66) |  |
Autologous stem cell transplantation | |||||||
 Done | 12 | (18) | 7 | (19) | 5 | (16) | 0.758 |
 Not done | 56 | (82) | 29 | (81) | 27 | (84) |  |
Relapse or progression | |||||||
 None | 25 | (37) | 18 | (50) | 7 | (22) | 0.023 |
 Occurred | 43 | (63) | 18 | (50) | 25 | (78) |  |
Survival status | |||||||
 Alive | 39 | (57) | 27 | (75) | 12 | (37) | 0.003 |
 Dead | 29 | (43) | 9 | (25) | 20 | (63) |  |